When stratifying by RA HLA risk, we observed a significant increase in the frequency of TIGIT+KLRG1+ TEX in risk RA HLA subjects (P = 0.0043), but not non-risk RA HLA subjects (P = 0.1250) following treatment with abatacept (Figure 5B). Here, KLRG1 is linked to rheumatoid arthritis.